價(jià)格 | ¥115 | ¥248 | ¥325 |
包裝 | 1mg | 5mg | 10mg |
最小起訂量 | 1mg |
發(fā)貨地 | 上海 |
更新日期 | 2024-09-24 |
中文名稱:化合物 Pimasertib | 英文名稱:Pimasertib |
CAS:1236699-92-5 | 品牌: TargetMol |
產(chǎn)地: 美國(guó) | 保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
純度規(guī)格: 98.25% | 產(chǎn)品類別: 抑制劑 |
貨號(hào): T6131 |
名稱 | Pimasertib |
描述 | Pimasertib (AS703026) is an orally bioavailable small-molecule inhibitor of MEK1 and MEK2 (MEK1/2) with potential antineoplastic activity. |
細(xì)胞實(shí)驗(yàn) | Method: Measuring incorporation of 14C-labelled thymidine into newly synthesized DNA within the cells to determine the ability of JNJ-7706621 to inhibit the proliferation of cell growth. Cells are trypsinized and counted and 3-8 ×103 cells are added to each well of a 96-well CytoStar tissue culture treated scintillating microplate in 100 μL complete medium in a volume. Cells are incubated for 24 hours at 37 °C in an atmosphere containing 5% CO2. Next, 1 μL JNJ-7706621 is added to the wells of the plate. Cells are incubated for another 24 hours. Methyl 14C-thymidine 56 mCi/mmol is diluted in complete medium and 0.2 μCi/well is added to each well of the CytoStar plate in a volume of 20 μL. The plate is incubated for 24 hours at 37 °C in JNJ-7706621 with 14C-thymidine. The contents of the plate are discarded and the plate is washed twice with 200 μL PBS. 200 μL of PBS is added to each well. The top of the plate is sealed with a transparent plate sealer and a white plate backing sealer is applied to the bottom of the plate. The degree of methyl 14C-thymidine incorporation is quantified on a Packard Top Count. |
激酶實(shí)驗(yàn) | The Aurora kinase activity is measured with 10 μM ATP and a peptide containing a dual repeat of the kemptide phosphorylation motif. |
體外活性 | 10 mg/kg AS703026抑制人類K-Ras突變 (D-MUT) 的結(jié)腸直腸移植瘤生長(zhǎng),且明顯降低p-ERK水平.15和30 mg/kg AS703026明顯抑制人類漿細(xì)胞H929 mM移植瘤生長(zhǎng),這可能與下調(diào)的pERK1/2,誘導(dǎo)的PARP切割和微血管減少相關(guān). |
體內(nèi)活性 | AS703026(10 μM)能有效抑制攜帶K-Ras突變等位基因(D-MUT)的人DLD-1結(jié)直腸癌細(xì)胞中的ERK途徑,增殖和轉(zhuǎn)化。AS703026抑制人類多發(fā)性骨髓瘤細(xì)胞(包括U266和INA-6細(xì)胞)生長(zhǎng)和存活,IC50分別為5和11 nM。AS703026的這種抑制作用由G0-G1細(xì)胞周期停滯介導(dǎo),并伴隨MAF致癌基因表達(dá)減少。在存在或不存在骨髓基質(zhì)細(xì)胞(BMSC)的情況下,AS703026通過(guò)半胱天冬酶-3和PARP在MM細(xì)胞中裂解進(jìn)一步誘導(dǎo)細(xì)胞凋亡。 AS703026可有效治療由K-Ras突變引起的結(jié)直腸癌。 |
存儲(chǔ)條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | Ethanol : < 1 mg/mL (insoluble or slightly soluble) DMSO : 45 mg/mL (104.36 mM), Sonication is recommended. |
關(guān)鍵字 | MAPKK | Inhibitor | SAR245509 | inhibit | MAP2K | MEK | Pimasertib | Mitogen-activated protein kinase kinase | AS-703026 | AS 703026 | SAR-245509 |
相關(guān)產(chǎn)品 | Lidocaine hydrochloride | PD 198306 | Pelitinib | Lidocaine | Honokiol | Refametinib R enantiomer | PD184161 | U0126-EtOH | Selumetinib | Refametinib | Binimetinib | Trametinib |
相關(guān)庫(kù) | 抑制劑庫(kù) | 抗癌活性化合物庫(kù) | 經(jīng)典已知活性庫(kù) | 已知活性化合物庫(kù) | 激酶抑制劑庫(kù) | 高選擇性抑制劑庫(kù) | 酪氨酸激酶分子庫(kù) | 藥物功能重定位化合物庫(kù) | 抗癌臨床化合物庫(kù) | 抗癌藥物庫(kù) |
成立日期 | 2013-04-18 (12年) | 注冊(cè)資本 | 566.2651萬(wàn)人民幣 |
員工人數(shù) | 100-500人 | 年?duì)I業(yè)額 | ¥ 1億以上 |
主營(yíng)行業(yè) | 化學(xué)試劑,生物活性小分子 | 經(jīng)營(yíng)模式 | 貿(mào)易,試劑,定制,服務(wù) |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢價(jià) |
VIP8年
|
山東辰熙醫(yī)藥科技有限公司
|
2024-10-30 | |
詢價(jià) |
VIP5年
|
上海澤葉生物科技有限公司
|
2024-10-30 | |
詢價(jià) |
VIP4年
|
河南威梯?;た萍加邢薰?/div>
|
2024-10-29 | |
詢價(jià) |
VIP10年
|
上海升德醫(yī)藥科技有限公司
|
2024-10-29 | |
詢價(jià) |
VIP4年
|
湖北諾迪納生物技術(shù)有限公司
|
2024-10-24 | |
¥600 |
VIP6年
|
無(wú)錫東禾醫(yī)藥科技有限公司
|
2024-10-21 | |
詢價(jià) |
南京百鑫德諾生物科技有限公司
|
2024-09-26 | ||
詢價(jià) |
VIP2年
|
陜西締都新材料有限公司
|
2024-09-02 | |
¥471.90 |
VIP13年
|
上海阿拉丁生化科技股份有限公司
|
2024-08-16 | |
詢價(jià) |
南京百鑫德諾生物科技有限公司
|
2024-09-26 |